PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

See How It Works? They Use ‘Woke’ Actions To Get You To Take Your Eye Off The Ball | They Fire Kanye For ‘Anti-Semitic’ Remarks While All The While Using Slave Labor | “From Apple to Adidas: Brands Use Ethnic Minority Slave Labor in China” | Medium

Show Me

Bannon’s War Room | Episode 2342 | Morning Edition Hour 2 | Recorded December 1, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Oh My, How The ‘Woke’ Are Just Tools Of The Corporate Behemoths | “Shareholders challenging Apple on unions & alleged slave labor” | Apple Insider

Show Me

Bannon’s War Room | Episode 2341 | Morning Edition Hour 1 | Recorded December 1, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2340 | Evening Edition | Recorded November 30, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Nightly News Rebroadcast | November 30, 2022 | Video: 26 Minutes 59 Seconds | NTD

Show Me

NTD News Today (Nov. 29, 2022): Protests Escalate in China’s Guangzhou; Former CCP Leader Jiang Zemin Dies at 96 | NTD

Show Me

Bannon’s War Room | Episode 2339 | Morning Edition Hour 2 | Recorded November 30, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2338 | Morning Edition Hour 1 | Recorded November 30, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Nightly News Rebroadcast | November 29, 2022 | Video: 26 Minutes 58 Seconds | NTD

Show Me

Bannon’s War Room | Episode 2337 | Evening Edition | Recorded November 29, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2336 | Morning Edition Hour 2 | Recorded November 29, 2022 | Video: 50 Minutes

Show Me

Bannon’s War Room | Episode 2335 | Morning Edition Hour 1 | Recorded November 29, 2022 | Video: 48 Minutes 58 Seconds

Show Me

The Woke Decry American Slavery That Ended Over 150 Years Ago While Enjoying The Benefits Of Slave Labor In Place Today | “In China, Human Costs Are Built Into an iPad” | The New York Times

Show Me

What Is The Real Reason Apple Wants Twitter Under Elon Musk To Go Away? The Slaves Are Revolting and Apple Can’t Stop Their Cries From Being Heard Worldwide | “I’m deeply concerned by @Apple ’s potential connection to the horrific crimes against humanity being committed in Xinjiang.” | Representative Ken Buck

Show Me

REPORT: More Suppliers for Apple Discovered Using Slave Labor | National Legal and Policy Center

Show Me

For Corporations That Use Slave Labor, Twitter Under Elon Musk Must Be Stopped Lest They Be Exposed To The ‘Woke’ | “‘Woke’ Apple continues to use Chinese slave labor, report shows” | The Washington Times

Show Me

Chang: China Protests Are Revolutionary | Newsmax | Video: 5 Minutes 11 Seconds

Show Me

Bannon’s War Room | Episode 2334 | Evening Edition | Recorded November 28, 2022 | Video: 48 Minutes 58 Seconds

Show Me

NTD News Today (Nov. 28, 2022): House GOP Asks 42 Biden Officials to Testify; Massive Protests Erupt Across China | NTD | Video: 28 Minutes 42 Seconds

Show Me

Bannon’s War Room | Episode 2333 | Morning Edition Hour 2 | Recorded November 28, 2022 | Video: 48 Minutes 59 Seconds

Show Me

Bannon’s War Room | Episode 2332 | Morning Edition Hour 1 | Recorded November 28, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Nightly News Rebroadcast | November 28, 2022 | Video: 26 Minutes 9 Seconds | NTD

Show Me

Elon Musk Says He Has a Plan If Twitter Gets Kicked Off App Stores | NTD and Epoch Times

Show Me

The Media’s Deranged Hysteria Over Elon Musk’s Restoration of Free Speech | Glenn Greenwald | Video: 34 Minutes 55 Seconds

Show Me

Perhaps The World Has Gone Mad | Calvin Klein Ads

Show Me

Bannon’s War Room | Episode 2331 | Saturday Edition Hour 2 | Recorded November 26, 2022 | Video: 48 Minutes 59 Seconds

Show Me

Bannon’s War Room | Episode 2330 | Saturday Edition Hour 1 | Recorded November 26, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Nightly News Rebroadcast | November 25, 2022 | Video: 26 Minutes 37 Seconds | NTD

Show Me

Bannon’s War Room | Episode 2329 | Morning Edition Hour 2 | Recorded November 25, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2328 | Morning Edition Hour 1 | Recorded November 25, 2022 | Video: 48 Minutes 59 Seconds

Show Me

US Government Was Investigating FTX Months Ago And Did Nothing Until After Midterms, Democrats Benefit | Bloomberg and Timcast | Video: 14 Minutes 22 Seconds

Show Me

Here’s To A Safe and Happy Thanksgiving | History.com

Show Me

Nightly News Rebroadcast | November 24, 2022 | Video: 23 Minutes 52 Seconds | NTD

Show Me

Bannon’s War Room | Episode 2327 | Morning Edition Hour 2 | Recorded November 24, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2326 | Morning Edition Hour 1 | Recorded November 24, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2325 | Evening Edition | Recorded November 23, 2022 | Audio: 48 Minutes 58 Seconds

Show Me

Nightly News Rebroadcast | November 23, 2022 | Video: 25 Minutes 26 Seconds | NTD

Show Me

World Premiere: Died Suddenly | Video: 1 Hour 8 Minutes 21 Seconds

Show Me

Bannon’s War Room | Episode 2324 | Morning Edition Hour 2 | Recorded November 23, 2022 | Video: 48 Minutes 58 Seconds

Show Me